Off-label prescription : practice and problems by Carneiro, António Vaz & Costa, João
Rev Port Cardiol. 2013;32(9):681--686
Revista Portuguesa de
Cardiologia
Portuguese Journal of Cardiology
www.revportcardiol.org
REVIEW ARTICLE
Off-label prescription: Practice and problems
António Vaz Carneiro ∗, João Costa
Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
Received 22 December 2012; accepted 19 January 2013
Available online 16 November 2013
KEYWORDS
Off-label
prescription;
Drug efficacy and
safety;
Drug indications;
Drug regulatory
approval processes
Abstract Approval of a drug for clinical use requires production of data on efficacy and
safety through submission of results from randomized controlled trials (RCTs), in which the
new molecule is usually compared with placebo (or an active comparator) for a set of out-
comes that will serve as the basis for the drug’s indications. These indications are crucial,
because drugs are approved on the basis of their net clinical benefit for specific and well-
defined diseases and--importantly--only for these. Once the drug is available for use in tens
or hundreds of thousands of patients, physicians may realize that some medications can be
effective in diseases for which they were not approved, i.e., no studies have been presented to
the regulatory authorities, and therefore they are not formally approved for those indications.
Convinced of the benefits for their patients, some physicians prescribe them for unapproved
indications--off-label prescription.
© 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights
reserved.
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A prescric¸ão fora das indicac¸ões aprovadas (off-label): prática e problemas
Resumo O processo de aprovac¸ão de medicamentos para uso clínico implica a produc¸ão de
provas de eficácia e seguranc¸a através da submissão de resultados de ensaios clínicos, em
que a nova molécula é comparada habitualmente ao placebo (ou a um comparador ativo)
para um conjunto de resultados nos quais se baseará a determinac¸ão das indicac¸ões. As
indicac¸ões são absolutamente cruciais, porque os fármacos são aprovados segundo o perfil
de benefício/risco que apresentam para tratamento de patologias específicas, bem definidas
e - um aspeto muito importante - apenas para estas. Uma vez estando o medicamento
disponível para ser utilizado em dezenas ou centenas de milhares de doentes, acontece por
vezes que, no decurso do seu uso regular e rotineiro, chega ao conhecimento dos médicos
que certas moléculas podem ser eficazes em situac¸ões para as quais não foram aprovadas,
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isto é, em que não foram apresentados estudos de suporte às autoridades regulamentares e que
portanto não estão legalmente aprovadas para essas indicac¸ões. Convictos dos benefícios para
os seus doentes, alguns médicos vão receitar medicamentos para indicac¸ões não aprovadas - a
chamada prescric¸ão off-label.
Neste artigo discute-se a prevalência da prescric¸ão off-label, assim como as suas vantagens
e inconvenientes.
© 2012 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L. Todos os
direitos reservados.
Introduction
A drug is only used in clinical practice after a complex
process of research and development that lasts on aver-
age 12-15 years, of which marketing authorization is the
penultimate step. This is granted by the European Medicines
Agency for all European countries. For such authorization to
be given, evidence must be provided of efficacy and safety
through submission of the results of phase 3 randomized con-
trolled trials (RCTs), in which the new molecule is compared
with placebo or an active comparator.
In most cases, the last step in the process is the adop-
tion of the drug by national authorities for outpatient and/or
hospital use. It is this step that, with rare exceptions, makes
the drug available to patients. This decision is taken when
the national authority (Infarmed in Portugal) makes a pos-
itive appraisal of the new drug’s health and/or economic
benefits (the latter through economic evaluation studies),
compared to the alternative reference therapy used in clin-
ical indications for the disease in question. Only if the new
drug constitutes a therapeutic innovation -- by filling a ther-
apeutic gap when compared with placebo, no treatment or
best supportive care -- will it be adopted. A substance is
not necessarily a therapeutic innovation simply because it
is new.1
Central to this process is the definition of indications for
the drug in question. These indications are crucial, because
drugs are approved (or not) on the basis of their net clinical
benefit for specific and well-defined diseases and -- impor-
tantly -- only for these.
Once the drug is granted marketing authorization, the
manufacturer can only market it for the approved indica-
tion(s); it is illegal to promote, directly or indirectly, or
even to suggest, its use for other diseases or other types of
patients (although this does happen2). Pharmaceutical com-
panies can add new indications to those already approved,
but they rarely do, because the clinical trials required are
lengthy and expensive and there is little incentive to con-
duct them, since the drug is already on the market. More
common are extensions to the approved indications, such as
to other age-groups or to different patient subtypes. Generic
drug manufacturers are likewise reluctant to conduct the
RCTs needed for new approvals, for the same financial rea-
sons.
Once the drug is available for use in tens or hundreds
of thousands of patients, physicians may realize that some
medications can be effective in diseases for which they were
not approved, i.e., no studies have been presented to the
regulatory authorities, and therefore they are not formally
approved for those indications. Convinced of the benefits
for their patients, some physicians prescribe them for unap-
proved indications -- off-label prescription.
Off-label prescription is thus defined as prescription for
an indication, disease, or patient outside the approved indi-
cations, or for populations that have not been studied (such
as pediatric patients), or using methods of administration
or dosages that have not been approved.3 The rationale for
off-label prescription is that the official agencies do not reg-
ulate the practice of medicine, and that physicians are free
to decide what they consider best for their patients.
There are two types of off-label prescription:
• the use of a drug that is indicated for a particular disease
in a completely different condition, such as anti-epileptic
agents for neuropathic pain;
• the use of a drug within its indications, but outside the
approved specifications, such as sildenafil, approved for
erectile dysfunction but used by patients without this
condition in order to enhance sexual performance.
The spectrum of off-label use includes guideline-
recommended practice (aspirin in diabetes for prophy-
laxis against cardiovascular disease), last-resort therapy
(tacrolimus for autoimmune diseases, in addition to trans-
plantation), and first-line therapy (gabapentin for painful
diabetic neuropathy).
Certain types of off-label prescription are of particular
concern and require careful scrutiny4:
• The off-label use of recently introduced drugs is a major
problem, since not only will there be virtually no evidence
of their benefit, but safety data from pharmacovigilance
will also be scarce, obviously complicating their use.
• Novel off-label use -- one that is different from usual clin-
ical practice -- has similar problems of lack of data on
efficacy and especially on safety, even if the drug itself
has been on the market for more than 3-5 years.
• When any drug with known serious or frequent adverse
effects is prescribed off-label, this use merits close atten-
tion owing to concerns for patient safety.
• Finally, off-label prescription of high-cost drugs raises
its own questions, since the financial penalty involved
demands particular practical reflection.
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In this paper we discuss some formal and practical
aspects of off-label prescription, including its prevalence,
advantages and disadvantages, and examine the nature of
the evidence supporting its use.
The prevalence of off-label prescription
So long as drugs prescribed off-label are safe, well tolerated
and inexpensive, the practice does not usually lead to major
problems. However, as stated above, problems arise with
high-cost drugs for specific diseases, a well-known example
of which is new biological drugs for the treatment of can-
cer; in some studies, off-label administration of these drugs
reaches 75%.5
In any event, whether for outpatient or in-hospital use,
off-label prescription occurs for almost all drug classes, with
a particularly high prevalence for certain drugs (Table 1).
In cardiology, a typical example of off-label prescription
is the use of new anticoagulants -- dabigatran, rivarox-
aban, apixaban -- in situations in which warfarin is the
first-line drug. A recent analysis examined other off-label
uses of cardiological drugs, including thrombin and factor Xa
inhibitors6; other common examples are the use of aspirin
for cardiological prevention in diabetic patients and of beta-
blockers for essential tremor.
For some drugs, of course, good evidence is available for
their use in particular conditions (such as beta-blockers for
essential tremor, as mentioned above7) but no formal indi-
cation has been approved; it should be borne in mind that
only the holder of the marketing authorization has the legal
right to alter or add to a drug’s indications, and that the
authorities cannot do so.
One well-publicized case of the existence of evidence for
an unapproved indication is of bevacizumab (Avastin®) for
age-related macular degeneration, for which the only drug
with formal indication is ranibizumab (Lucentis®). A non-
inferiority clinical trial comparing the two, the CATT trial,8
concluded that ranibizumab and bevacizumab had equiva-
lent effects on visual acuity at one year and that differences
in rates of serious adverse events require further study.
Another example of off-label prescription is the use of
recombinant factor VIIa.9 Initially approved only for the
treatment of hemophilia, especially in patients who have
developed factor VII inhibitors, recombinant factor VIIa is
used as a hemostatic agent in cardiac surgery, trauma and
intracranial hemorrhage, to the point that prescription for
approved indications accounts for only 3% of cases.10
The prevalence of off-label prescription has not received
the attention that it warrants. Various numbers appear in
the literature, ranging from 20%11 to 50% (Pharmaceutical
Executive 2012) of prescriptions in the US, 60% in some Aus-
tralian hospitals (Discussion Paper Working Group of NSW
TAG, 2003), 30% in outpatients in the UK (NICE 2012) and
23% in Europe.12 The most frequently cited study,13 based on
a US survey of outpatient prescriptions, reports an overall
rate of 21% of off-label prescription, rising to 46% of cardiac
medications (excluding lipid-lowering and antihypertensive
medications) and of anticonvulsants. Gabapentin had the
highest proportion of off-label prescription (83%), followed
by amitriptyline (81%). In most cases (73%) there was no
evidence to back up the use of these drugs outside their
approved indications.
To summarize, off-label prescription is very common, and
the drug classes involved are generally the more complex
ones.
The advantages of off-label prescription
Off-label prescription may occur for a variety of different
reasons6:
1. a class effect, by which drugs of the same class are pre-
sumed have similar effects in a particular disease (for
example, the use of a statin for primary prevention that
has only been studied for secondary prevention);
2. extension of therapies approved for severe clinical situa-
tions to milder forms, such as the use of spironolactone,
approved for patients in NYHA classes III and IV, for
patients in classes I and II14,15;
3. extension to related conditions (use of the antiasthmatic
montelukast for chronic obstructive pulmonary disease);
4. expansion to distinct conditions sharing a physiological
link (use of the antidiabetic drug metformin to treat
polycystic ovarian syndrome); and
5. extension to conditions whose symptoms overlap with
those of an approved indication, in the belief that the
off-label treatment will be equally effective (gabapentin
for non-neuropathic pain syndromes).
Besides these justifications for off-label prescription,
there are other arguments in its favor6,11: it enables new
indications to be discovered, particularly when approved
treatments have failed; it can dispense with the lengthy and
costly drug approval process via official agencies, offering
earlier access to drugs and adoption of new practices based
on emerging evidence (and thereby enabling physicians to
accumulate evidence prior to official approval); and exper-
imentation with new drugs can be justified for many less
common diseases for which there are no effective approved
treatments.
Furthermore, there are some circumstances in which
there is no alternative to off-label prescription. The most
obvious example of this is pediatrics. Since very few clinical
trials are performed in children, most drugs used in pedi-
atric populations do not have approved indications. Another
example is in certain rare diseases that also lack approved
treatments due to the impossibility of carrying out effec-
tive clinical trials; here also the only possible treatment may
be with drugs approved for other conditions. But off-label
prescription for common conditions also occurs in clinical
practice; for example, the use of beta-blockers in conges-
tive heart failure began before there were clinical trials to
support this indication.
Problems with off-label prescription
Given the complex and painstaking process of approval
and introduction that new drugs must go through, which
is intended to ensure both their efficacy and safety, any
use outside the indications for which they were evaluated
naturally raises important questions.
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Table 1 Drugs commonly prescribed off-label (Consumer Reports Best Buy Drugs, www.CRBestBuyDrugs.org, accessed August
2012).20
Type of drug Examples of off-label use
Anti-seizure drugs Migraines, depression, nerve pain
Antipsychotics Alzheimer’s disease, autism, dementia, ADHD
Antidepressants Chronic pain, ADHD, bipolar disorder
Antihistamines Colds, asthma, ear infection symptoms, as sleep aids
Antibiotics Viral infections (colds and influenza)
Anxiety drugs To ease ‘‘normal’’ life stresses, as sleep aids
Proton pump inhibitors Occasional heartburn, indigestion, irritable bowel
Beta-blockers Migraine, heart rhythm disorders, anxiety
Drugs to treat ADHD For people not diagnosed with ADHD, to enhance
alertness and concentration
Insomnia medicines For people with infrequent insomnia, insomnia
associated with depression, anxiety
Narcotic pain relievers For people with only mild, infrequent pain
Specific drugs Examples of off-label use
Aripiprazole (antipsychotic) Dementia, Alzheimer’s disease
Albuterol (for asthma) Bad coughs
Lamictal (antiepileptic, anti-seizure) Depression, bipolar disorder, mood stabilization
Tiagabine (antiepileptic) Depression, mood stabilization
Gabapentin (antiepileptic) Depression, nerve pain, migraines
Topiramate (antiepileptic) Migraines, bipolar disorder, depression, nerve pain
Risperidone (antipsychotic) Alzheimer’s disease, dementia, eating disorders
Lidoderm (skin patch for shingles) Lower back pain, sore muscles, tennis elbow
Trazodone (antidepressant) As a sleep aid and for insomnia
Propranolol (high blood pressure and heart disease) Performance anxiety
Modafinil (for excessive sleepiness) To enhance wakefulness and alertness
Sildenafil, vardenafil, tadalafil (erectile dysfunction) To enhance sexual performance in people not diagnosed
with erectile dysfunction
Bevacizumab Wet age-related macular degeneration
ADHD: attention deficit/hyperactivity disorder.
Prescription of a drug outside its approved indications will
increase the individual physician’s civil and criminal respon-
sibility. It has been suggested that physicians should in some
cases be obliged to provide patients with information on
the risks of off-label prescription and to obtain their con-
sent -- a similar process to the informed consent process.11
In times of economic constraints other considerations come
into play, since health authorities -- whether local (hospitals
and family health centers), regional or national -- are under
increasing pressure to audit and monitor drug prescriptions
and to take measures, individually and collectively, to ratio-
nalize their use.
Unlike physicians, the drug manufacturers have little
legal liability with regard to off-label prescription, since
they can only be held responsible for problems that arise
when their product is used within its approved indications.
Furthermore, off-label prescription may in fact discourage
the pharmaceutical industry from conducting clinical trials
for new or different indications (thereby reducing public
confidence in the drug evaluation process), encourage ever
wider use in unstudied populations such as children and
the elderly, and, when the drugs in question are expensive,
increase health care costs.
One of the main concerns with off-label prescription is
the lack of effective pharmacovigilance due to a low level
of reporting, which may obscure safety issues. It should be
recalled that drugs with a good safety profile for a spe-
cific use, prescribed for the studied population and with the
approved indications, may not be safe with unapproved use
and/or in unstudied patient groups.
An example of this is the CATT trial referred to above,
which compared ranibizumab (the approved drug) and beva-
cizumab (unapproved) for the treatment of age-related
macular degeneration, and which revealed differences in
serious adverse effects between the two.8,16 Although the
differences did not permit firm conclusions to be drawn, the
authors stated that further studies were required to assess
the safety of the two drugs, particularly bevacizumab. This
led to a recent systematic review directly comparing three
RCTs, including the CATT trial, with a total of 1333 patients,
that assessed the safety of off-label use of bevacizumab vs.
ranibizumab for the same indications.17 The results showed
that bevacizumab has a significantly higher rate of ocular
adverse effects (risk ratio [RR] 2.8; 95% confidence interval
[CI] 1.2-6.5) and serious infections and gastrointestinal dis-
orders (RR 1.3; 95% CI 1.0-1.7). In indirect comparisons with
a variety of controls (5 RCTs, 4054 patients), and based on
the two-year results of three landmark trials, the risk of ocu-
lar adverse effects was higher for bevacizumab (RR 3.1; 95%
CI 1.1-8.9), even though the absolute baseline risk for these
patients was low (2.1%). A significant increase in nonocular
hemorrhage was observed with ranibizumab (RR 1.7; 95% CI
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1.1-2.7), while no difference was detected in the incidence
of arterial thromboembolic events.
As well as providing a better characterization of the
safety of off-label bevacizumab, this review included
several studies and was thus better able to find differences
between the drugs, thereby partly overcoming the limi-
tations of individual trials to identify safety issues. The
consequence in this case has been a change in the Summary
of Product Characteristics for bevacizumab, which now
include the risk of ocular adverse reactions following unap-
proved intravitreal use of bevacizumab under the heading
‘‘Special warnings and precautions for use’’ (http://www.
ema.europa.eu/docs/en GB/document library/EPAR -
Product Information/human/000582/WC500029271.pdf,
accessed October 31, 2012).
Besides the potential safety issues with off-label beva-
cizumab, the results of the CATT trial are a classic example
of the limited ability of clinical trials to characterize the
safety and tolerability of drug therapies, particularly when
adverse events are uncommon (though serious) and/or occur
late, due to the limited number of patients and duration of
the trial. A well-known recent example was the cardiovas-
cular risk of cyclooxygenase inhibitors.18 Most clinical trials
now have open extensions, during which patients are treated
for a specific period (usually until the new drug is licensed).
The main aim of such extensions is to evaluate safety and
tolerability.
The evidence for off-label prescription
As stated above, the evidence produced by the original
investigation is mainly intended for the regulatory approval
process of new drugs with a view to their introduction to the
market. However, there may be evidence that could serve as
the basis for the drug to be used outside its approved indi-
cations. In this case, the question is whether the physician
can justify off-label prescription if there is good evidence
to support the practice.
In our opinion, routine off-label use of drugs may be jus-
tified if there is high-quality (real-world) evidence that they
are effective and safe, and that their overall risk/benefit
ratio is acceptable for a specific context (such as data on
long-term use in chronic diseases).3
One proposed classification of evidence that could sup-
port off-label prescription divides it into supported evidence
(with a moderate to high level of certainty of net health ben-
efits), suppositional evidence (a low level of certainty), and
investigational evidence (unknown level).4
One of the more complicated problems with evidence
that may support off-label prescription is that it can be
presented in a variety of ways, some of which lack rigor. A
recent study of compendia of indications for off-label oncol-
ogy treatments19 found that they cited little of the available
evidence, often neither the most recent nor that of highest
methodological quality, and were analyzed on a completely
random basis. For the 14 off-label indications studied, the
compendia differed in the indications included and whether
and how they recommended particular agents for particular
types of cancer.
To summarize, off-label use of a drug may be justi-
fied if there is high-quality evidence to support such use,
bearing in mind that the results may differ markedly from
those obtained when the drug is used within its approved
indications.
Conclusions
Off-label prescription is an inescapable aspect of modern
health care systems.
In this paper we set out to examine the need to obtain
evidence to support the use of drugs outside their approved
indications and thereby to promote rational and evidence-
based prescription. Such use should always be an exception,
to reduce inappropriate use and to ensure patients’
safety.
When prescribing, the physician should pay particular
attention to the adverse effects of off-label use and when-
ever possible should obtain supporting evidence.
Although we recognize that in certain areas, such as pedi-
atrics and oncology, off-label prescription is inevitable, we
argue that it should always be an exception and should be
supported by high-quality evidence that the physician must
be able to explain.
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